Form 4: Niagen Bioscience Director Ann Cohen Granted 20,000 Stock Options

Niagen Bioscience, Inc. Director Ann Cohen was granted 20,000 stock options with an exercise price of $14.13, vesting fully on June 24, 2026.

Summary

• Ann Cohen, a Director of Niagen Bioscience, Inc. (NAGE), acquired 20,000 stock options.
• The options have an exercise price of $14.13 per share.
• The transaction date for the option grant was June 24, 2025.
• These options will vest 100% on June 24, 2026.
• The options have an expiration date of June 23, 2035.
• Following this transaction, Ann Cohen directly beneficially owns 20,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally viewed positively as it aligns the director's financial interests with the long-term performance of the company and shareholder value.

Positives

• The grant of stock options to a director indicates continued alignment of management interests with shareholder value.
• The options provide an incentive for the director to contribute to the company's long-term success.

Risks

• The value of the options is dependent on the future stock price of Niagen Bioscience, Inc. exceeding the exercise price of $14.13.
• If the stock price does not rise above the exercise price, the options may expire worthless.

Future Outlook

The options are designed to incentivize the director over a long-term horizon, with a vesting date in 2026 and an expiration date in 2035, suggesting a focus on long-term value creation.

Industry Context

The granting of stock options is a common practice in many industries, including biotechnology, to align the interests of directors and executives with those of shareholders, particularly in growth-oriented companies like Niagen Bioscience.

Comparison to Industry Standards

• The specific terms of the option grant (exercise price, vesting schedule, expiration date) would typically be compared against similar grants to directors in companies of comparable size and stage within the biotechnology or pharmaceutical industry. Without specific industry benchmarks or comparable company data within the document, a detailed comparison is not possible. However, option grants are a standard component of director compensation packages across various industries.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to more focused efforts on increasing share value. It signals confidence from an insider.

Next Steps

• The options will vest 100% on June 24, 2026.
• The options can be exercised at any time after vesting until their expiration on June 23, 2035, assuming the stock price is above the exercise price.

Key Dates

Keywords

Niagen Bioscience, NAGE, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, Ann Cohen